Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Bond Kinetics Underlie von Willebrand's Disease

By Biotechdaily staff writers
Posted on 08 Jul 2002
A study has shown that the exceptional persistence of temporary chemical bonds between blood platelets and the von Willebrand factor (vWF) clotting protein underlies the bleeding disorder known as type IIb von Willebrand's disease. More...
The results, published in the July 2002 issue of Biophysical Journal, suggest that the disease occurs because a defective form of vWF allows vWF-platelet complexes to last longer than they should.

Until recently it was thought that substitution of one amino acid in defective vWF caused a conformational change that stabilized the bond between the protein and platelets. The findings of the current study support a different explanation, however. Investigators from the Washington University School of Medicine (St. Louis, MO, USA) found that bond kinetics, the rate at which chemical bonds form and dissociate, rather than a conformational change, is responsible.

"This is the first time that a naturally occurring disease has been linked to an alteration in the kinetic properties of a chemical bond,” explained study leader Dr. Thomas G. Diacovo, assistant professor of pediatrics, pathology, and immunology. "The finding should give us a better understanding of how normal platelets function and of the delicate balance that exists between these blood-clotting elements. Disturb that balance, and the whole system falls apart.”

The importance of bond kinetics had previously been demonstrated for a family of proteins called selectins, which are involved in the recruiting of white blood cells to inflamed blood vessel walls. Working with platelets in the current study, the researchers found that in normal individuals a few transient bonds form between circulating platelets and vWF. In type IIb von Willebrand's disease, however, the bonds last significantly longer than normal. That extra time allows many additional bonds to form, which stabilizes the interaction.

"It is not just a brief touch-and-go,” said Dr. Diacovo. "Rather, one bond forms and before it breaks, two, three, and four more have formed.” As more bonds form, small aggregates of platelets and vWF develop. These aggregates are removed from the blood, which reduces the amount of vWF and the number of platelets in circulation. Consequently, people with von Willebrand's disease have a mild-to-moderate bleeding disorder. They bruise easily and simple nosebleeds can continue for several hours or days before finally healing.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Immunoassay Analyzer
Procise DX
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.